enVVeno Medical (NASDAQ:NVNO) Stock Rating Upgraded by LADENBURG THALM/SH SH

enVVeno Medical (NASDAQ:NVNO) was upgraded by stock analysts at LADENBURG THALM/SH SH from a “hold” rating to a “strong-buy” rating in a report issued on Monday,Zacks.com reports.

Separately, Weiss Ratings cut enVVeno Medical from a “sell (d-)” rating to a “sell (e+)” rating in a report on Tuesday, June 30th. One research analyst has rated the stock with a Strong Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy”.

enVVeno Medical Stock Up 2.6%

Shares of NASDAQ:NVNO traded up $0.29 during midday trading on Monday, hitting $11.39. 10,348 shares of the stock traded hands, compared to its average volume of 15,843. The stock has a market capitalization of $7.63 million, a PE ratio of -0.45 and a beta of 1.09. The business’s 50 day moving average is $10.62 and its two-hundred day moving average is $10.95. enVVeno Medical has a one year low of $8.67 and a one year high of $196.70.

enVVeno Medical (NASDAQ:NVNO) last posted its earnings results on Thursday, May 7th. The company reported ($5.89) earnings per share (EPS) for the quarter, topping the consensus estimate of ($8.40) by $2.51.

Institutional Trading of enVVeno Medical

Several institutional investors and hedge funds have recently bought and sold shares of NVNO. ACT Capital Management LLC purchased a new position in shares of enVVeno Medical during the 4th quarter worth approximately $37,000. Jane Street Group LLC bought a new stake in shares of enVVeno Medical during the second quarter valued at approximately $51,000. Creative Planning bought a new stake in shares of enVVeno Medical during the second quarter valued at approximately $54,000. CM Management LLC grew its stake in enVVeno Medical by 108.3% in the fourth quarter. CM Management LLC now owns 1,250,000 shares of the company’s stock worth $401,000 after purchasing an additional 650,000 shares during the period. Finally, Geode Capital Management LLC grew its stake in enVVeno Medical by 1.1% in the second quarter. Geode Capital Management LLC now owns 199,509 shares of the company’s stock worth $796,000 after purchasing an additional 2,211 shares during the period. 34.71% of the stock is currently owned by hedge funds and other institutional investors.

enVVeno Medical Company Profile

enVVeno Medical, Inc is a clinical‐stage medical device company focused on the development and commercialization of subcutaneous vascular access systems for patients requiring repeated or long‐term intravenous therapy. Through its proprietary Freedom® platform, the company aims to offer an implantable alternative to traditional peripherally inserted central catheters (PICCs) and external tunneled catheters, addressing complications such as infection risk, dislodgement and patient discomfort.

The company’s lead product candidate, the Freedom PICC System, consists of a low‐profile, subcutaneous port connected to a flexible catheter designed for peripheral insertion.